Familial pancreatic cancer (Part II): Surveillance, diagnostic tests, and surgical strategies.

H. T. Lynch, M. L. Fitzsimmons, J. McClellan, S. J. Lanspa, R. J. Fitzgibbons, Thomas Christopher Smyrk

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We have provided a description of the current state of knowledge relevant to familial/hereditary pancreatic cancer. Since the most important clinical ramifications of this disease, whose incidence and mortality are essentially the same, rests upon its earlier detection, we have also characterized available diagnostic tests, surgical strategies, and current knowledge about its pathology. We believe that advances in control of pancreatic cancer will be heavily impacted by progress in the search for new and better diagnostic tests. These could include monoclonal antibodies targeted to pancreatic tumor tissue, and possibly pancreatic site-specific P450's, as well as biomolecular/genetic techniques, particularly when focused on individuals at high risk. Thus, family studies are important in this disease because if an autosomal dominantly inherited form of pancreatic cancer is delineated, one could identify individuals at high risk early in life. Comparison could then be made with individuals in branches of the family where the disease is not segregating. Thus, there would be a greater potential for discovery of methods for early detection with evaluation of sensitivity and specificity in families wherein the predictability for pancreatic cancer occurrence is high.

Original languageEnglish (US)
Pages (from-to)130-133
Number of pages4
JournalThe Nebraska medical journal
Volume75
Issue number6
StatePublished - Jun 1990
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Routine Diagnostic Tests
Genetic Techniques
Monoclonal Antibodies
Pathology
Sensitivity and Specificity
Mortality
Incidence
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lynch, H. T., Fitzsimmons, M. L., McClellan, J., Lanspa, S. J., Fitzgibbons, R. J., & Smyrk, T. C. (1990). Familial pancreatic cancer (Part II): Surveillance, diagnostic tests, and surgical strategies. The Nebraska medical journal, 75(6), 130-133.

Familial pancreatic cancer (Part II) : Surveillance, diagnostic tests, and surgical strategies. / Lynch, H. T.; Fitzsimmons, M. L.; McClellan, J.; Lanspa, S. J.; Fitzgibbons, R. J.; Smyrk, Thomas Christopher.

In: The Nebraska medical journal, Vol. 75, No. 6, 06.1990, p. 130-133.

Research output: Contribution to journalArticle

Lynch, HT, Fitzsimmons, ML, McClellan, J, Lanspa, SJ, Fitzgibbons, RJ & Smyrk, TC 1990, 'Familial pancreatic cancer (Part II): Surveillance, diagnostic tests, and surgical strategies.', The Nebraska medical journal, vol. 75, no. 6, pp. 130-133.
Lynch HT, Fitzsimmons ML, McClellan J, Lanspa SJ, Fitzgibbons RJ, Smyrk TC. Familial pancreatic cancer (Part II): Surveillance, diagnostic tests, and surgical strategies. The Nebraska medical journal. 1990 Jun;75(6):130-133.
Lynch, H. T. ; Fitzsimmons, M. L. ; McClellan, J. ; Lanspa, S. J. ; Fitzgibbons, R. J. ; Smyrk, Thomas Christopher. / Familial pancreatic cancer (Part II) : Surveillance, diagnostic tests, and surgical strategies. In: The Nebraska medical journal. 1990 ; Vol. 75, No. 6. pp. 130-133.
@article{d18a4ad70d8a4c47b87e876188ae9d44,
title = "Familial pancreatic cancer (Part II): Surveillance, diagnostic tests, and surgical strategies.",
abstract = "We have provided a description of the current state of knowledge relevant to familial/hereditary pancreatic cancer. Since the most important clinical ramifications of this disease, whose incidence and mortality are essentially the same, rests upon its earlier detection, we have also characterized available diagnostic tests, surgical strategies, and current knowledge about its pathology. We believe that advances in control of pancreatic cancer will be heavily impacted by progress in the search for new and better diagnostic tests. These could include monoclonal antibodies targeted to pancreatic tumor tissue, and possibly pancreatic site-specific P450's, as well as biomolecular/genetic techniques, particularly when focused on individuals at high risk. Thus, family studies are important in this disease because if an autosomal dominantly inherited form of pancreatic cancer is delineated, one could identify individuals at high risk early in life. Comparison could then be made with individuals in branches of the family where the disease is not segregating. Thus, there would be a greater potential for discovery of methods for early detection with evaluation of sensitivity and specificity in families wherein the predictability for pancreatic cancer occurrence is high.",
author = "Lynch, {H. T.} and Fitzsimmons, {M. L.} and J. McClellan and Lanspa, {S. J.} and Fitzgibbons, {R. J.} and Smyrk, {Thomas Christopher}",
year = "1990",
month = "6",
language = "English (US)",
volume = "75",
pages = "130--133",
journal = "The Nebraska medical journal",
issn = "0091-6730",
publisher = "Nebraska State Medical Association",
number = "6",

}

TY - JOUR

T1 - Familial pancreatic cancer (Part II)

T2 - Surveillance, diagnostic tests, and surgical strategies.

AU - Lynch, H. T.

AU - Fitzsimmons, M. L.

AU - McClellan, J.

AU - Lanspa, S. J.

AU - Fitzgibbons, R. J.

AU - Smyrk, Thomas Christopher

PY - 1990/6

Y1 - 1990/6

N2 - We have provided a description of the current state of knowledge relevant to familial/hereditary pancreatic cancer. Since the most important clinical ramifications of this disease, whose incidence and mortality are essentially the same, rests upon its earlier detection, we have also characterized available diagnostic tests, surgical strategies, and current knowledge about its pathology. We believe that advances in control of pancreatic cancer will be heavily impacted by progress in the search for new and better diagnostic tests. These could include monoclonal antibodies targeted to pancreatic tumor tissue, and possibly pancreatic site-specific P450's, as well as biomolecular/genetic techniques, particularly when focused on individuals at high risk. Thus, family studies are important in this disease because if an autosomal dominantly inherited form of pancreatic cancer is delineated, one could identify individuals at high risk early in life. Comparison could then be made with individuals in branches of the family where the disease is not segregating. Thus, there would be a greater potential for discovery of methods for early detection with evaluation of sensitivity and specificity in families wherein the predictability for pancreatic cancer occurrence is high.

AB - We have provided a description of the current state of knowledge relevant to familial/hereditary pancreatic cancer. Since the most important clinical ramifications of this disease, whose incidence and mortality are essentially the same, rests upon its earlier detection, we have also characterized available diagnostic tests, surgical strategies, and current knowledge about its pathology. We believe that advances in control of pancreatic cancer will be heavily impacted by progress in the search for new and better diagnostic tests. These could include monoclonal antibodies targeted to pancreatic tumor tissue, and possibly pancreatic site-specific P450's, as well as biomolecular/genetic techniques, particularly when focused on individuals at high risk. Thus, family studies are important in this disease because if an autosomal dominantly inherited form of pancreatic cancer is delineated, one could identify individuals at high risk early in life. Comparison could then be made with individuals in branches of the family where the disease is not segregating. Thus, there would be a greater potential for discovery of methods for early detection with evaluation of sensitivity and specificity in families wherein the predictability for pancreatic cancer occurrence is high.

UR - http://www.scopus.com/inward/record.url?scp=0025443546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025443546&partnerID=8YFLogxK

M3 - Article

C2 - 2195363

AN - SCOPUS:0025443546

VL - 75

SP - 130

EP - 133

JO - The Nebraska medical journal

JF - The Nebraska medical journal

SN - 0091-6730

IS - 6

ER -